Nuron Biotech Licenses HibTITER® Vaccine to Mitsubishi Tanabe Pharma Corporation for Japanese Market  
1/13/2012 6:30:43 AM

EXTON, Pa.--(BUSINESS WIRE)--Nuron Biotech Inc., a specialty biologics and vaccines company, today announced that it has licensed its HibTITER® vaccine to Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka, Japan; “MTPC”) for commercialization in the Japanese market for both the single entity and for combination product use. Under the terms of the agreement MTPC will be responsible for any necessary development and regulatory approval costs, pay undisclosed upfront, pre-commercial milestones and pay Nuron Biotech significant royalties on commercial sales in Japan.